Disclosure statement
NJ: Research funding to institution from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, and Precision Biosciences for clinical studies in which NJ is a principal investigator, advisory board member and honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies, Servier, and Precision Biosciences; PT: Research funding to institution from Pharmacyclics, AbbVie, Genentech and AstraZeneca, advisory board member and honoraria from Pharmacyclics, AbbVie, Gilead, Genentech, speaking fees from Janssen; MF, SLA, WW, DPK, AJD: no relevant disclosures.